Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive global study to track rare heart and nerve disease in real life

NCT ID NCT06465810

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 4 times

Summary

This study will follow about 1,850 people with ATTR amyloidosis, a rare disease that affects the heart and nerves. Researchers will collect information on patients' health, treatments, and outcomes over time to better understand the disease and how current therapies work in everyday practice. No experimental treatments are given; it is purely observational.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,850 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of amyloid transthyretin (ATTR) amyloidosis

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient willing and able to provide written informed consent to participate in the study * Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis * Aged ≥18 years at the time of signing the informed consent * Patient willing and able to participate in collection of electronic patient reported outcomes (PROs) Exclusion Criteria: * Concurrent participation in any interventional trial for ATTR amyloidosis * Involvement in the planning and/or conduct of the current study * Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA) * Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies Amyloid Neuropathies, Familial amyloidosis familial amyloid neuropathy hereditary amyloidosis polyneuropathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTR Attr-CM Attr-mixed Attrv-PN HATTR Transthyretin amyloidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    89 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    La Jolla, California, 92037, United States

  • Research Site

    RECRUITING

    Los Angeles, California, 90095, United States

  • Research Site

    RECRUITING

    San Francisco, California, 94025, United States

  • Research Site

    RECRUITING

    San Francisco, California, 94143, United States

  • Research Site

    RECRUITING

    New Haven, Connecticut, 006510, United States

  • Research Site

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

  • Research Site

    RECRUITING

    Chicago, Illinois, 60637, United States

  • Research Site

    RECRUITING

    Indianapolis, Indiana, 06200, United States

  • Research Site

    RECRUITING

    Baltimore, Maryland, 21218, United States

  • Research Site

    RECRUITING

    Boston, Massachusetts, 02111, United States

  • Research Site

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • Research Site

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Research Site

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Research Site

    RECRUITING

    Kansas City, Missouri, 64111, United States

  • Research Site

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Research Site

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Research Site

    RECRUITING

    Manhasset, New York, 11030, United States

  • Research Site

    NOT_YET_RECRUITING

    New York, New York, 10016, United States

  • Research Site

    RECRUITING

    New York, New York, 10027, United States

  • Research Site

    RECRUITING

    New York, New York, 10029, United States

  • Research Site

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Research Site

    RECRUITING

    Portland, Oregon, 97239, United States

  • Research Site

    RECRUITING

    Danville, Pennsylvania, 17822, United States

  • Research Site

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Research Site

    RECRUITING

    Greenville, South Carolina, 29607, United States

  • Research Site

    RECRUITING

    Germantown, Tennessee, 38138, United States

  • Research Site

    RECRUITING

    Nashville, Tennessee, 037214, United States

  • Research Site

    RECRUITING

    Dallas, Texas, 75246, United States

  • Research Site

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    RECRUITING

    Richmond, Virginia, 23298, United States

  • Research Site

    RECRUITING

    Seattle, Washington, 98915, United States

  • Research Site

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Research Site

    RECRUITING

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Research Site

    RECRUITING

    Vancouver, British Columbia, V6Z 1Y6, Canada

  • Research Site

    RECRUITING

    Halifax, Nova Scotia, B3RIV9, Canada

  • Research Site

    RECRUITING

    London, Ontario, N6A 5A5, Canada

  • Research Site

    RECRUITING

    Toronto, Ontario, M2J 4W8, Canada

  • Research Site

    NOT_YET_RECRUITING

    Montreal, Quebec, H2X 0A9, Canada

  • Research Site

    NOT_YET_RECRUITING

    Rimouski, Quebec, G5L 5T1, Canada

  • Research Site

    NOT_YET_RECRUITING

    Hefei, Anhui, 230001, China

  • Research Site

    RECRUITING

    Beijing, Beijing Municipality, 100029, China

  • Research Site

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

  • Research Site

    RECRUITING

    Beijing, Beijing Municipality, 100191, China

  • Research Site

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

  • Research Site

    RECRUITING

    Chongqing, Chongqing Municipality, 400000, China

  • Research Site

    NOT_YET_RECRUITING

    Fuzhou, Fujian, 350005, China

  • Research Site

    RECRUITING

    Xiamen, Fujian, 361016, China

  • Research Site

    RECRUITING

    Guangzhou, Guangdong, 510080, China

  • Research Site

    RECRUITING

    Guangzhou, Guangdong, 510515, China

  • Research Site

    NOT_YET_RECRUITING

    Guiyang, Guizhou, 550004, China

  • Research Site

    NOT_YET_RECRUITING

    Shijiazhuang, Hebei, 050000, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430000, China

  • Research Site

    RECRUITING

    Wuhan, Hubei, 430030, China

  • Research Site

    NOT_YET_RECRUITING

    Changsha, Hunan, 410011, China

  • Research Site

    RECRUITING

    Changsha, Hunan, 410013, China

  • Research Site

    RECRUITING

    Nanjing, Jiangsu, 210029, China

  • Research Site

    NOT_YET_RECRUITING

    Suzhou, Jiangsu, 215006, China

  • Research Site

    RECRUITING

    Nanchang, Jiangxi, 330000, China

  • Research Site

    NOT_YET_RECRUITING

    Dalian, Liaoning, 116011, China

  • Research Site

    RECRUITING

    Jinan, Shandong, 250012, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200031, China

  • Research Site

    RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

  • Research Site

    NOT_YET_RECRUITING

    Taiyuan, Shanxi, 030001, China

  • Research Site

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • Research Site

    RECRUITING

    Chengdu, Sichuan, 610072, China

  • Research Site

    RECRUITING

    Shaanxi, Xi'An, 710061, China

  • Research Site

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310009, China

  • Research Site

    NOT_YET_RECRUITING

    Würzburg, Bavaria, DE-97072, Germany

  • Research Site

    RECRUITING

    Frankfurt am Main, Hesse, 60590, Germany

  • Research Site

    RECRUITING

    Hanover, Lower Saxony, 30625, Germany

  • Research Site

    RECRUITING

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Research Site

    RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Research Site

    RECRUITING

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Research Site

    RECRUITING

    Homburg, Saarland, 66421, Germany

  • Research Site

    RECRUITING

    Berlin, 10117, Germany

  • Research Site

    RECRUITING

    Huelva, Andalusia, 21005, Spain

  • Research Site

    RECRUITING

    Bilbao, Basque Country, 48013, Spain

  • Research Site

    RECRUITING

    Las Palmas de Gran Canaria, Canary Islands, 35010, Spain

  • Research Site

    RECRUITING

    Salamanca, Castille and León, 37007, Spain

  • Research Site

    RECRUITING

    Barcelona, Catalu A, 08035, Spain

  • Research Site

    NOT_YET_RECRUITING

    Barcelona, Catalu A, 8036, Spain

  • Research Site

    NOT_YET_RECRUITING

    Cataluna, Catalu A, 08907, Spain

  • Research Site

    RECRUITING

    Majadahonda, Madrid, 28222, Spain

  • Research Site

    RECRUITING

    Islas Baleares, Palma de Mallorca, 07198, Spain

  • Research Site

    RECRUITING

    Birmingham, West Midlands, B15 2GW, United Kingdom

  • Research Site

    RECRUITING

    Glasgow, G51 4TF, United Kingdom

  • Research Site

    RECRUITING

    London, NW3 2QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.